Physician profile
Benjamin Y Lee
NPI 1306811955
$1,532.07
in general payments reported to CMS, 2019-2025
18 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $32.08 · 2021: $55.43 · 2022: $199 · 2023: $515 · 2024: $250 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $245.03 | 2021-2025 | |
| Lilly USA, LLC | $239.42 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $202.50 | 2019-2020 | |
| Novo Nordisk INC | $182.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $181.66 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $96.59 | 2023-2025 | Otezla, Repatha, Repatha |
| Optinose US, INC. | $88.76 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.78 | 2023-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $47.92 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $30.99 | 2024 | |
| Astellas Pharma US INC | $22.60 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $21.54 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $20.80 | 2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $20.71 | 2023 | Breztri |
| Verona Pharma, INC. | $18.03 | 2025 | Ohtuvayre |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.94 | 2023 | |
| Mylan Specialty L.P. | $15.80 | 2023 | Yupelri |
| Esperion Therapeutics, INC. | $14.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.